Kent Hawryluk, MBX Biosciences CEO
September 9, 2024 07:35 AM EDT
Financing
Startups

MBX seeks $114M IPO to com­pete with As­cendis and get a long-act­ing GLP-1/GIP pro­drug in­to the clin­ic

Kyle LaHucik

Senior Reporter

MBX Bio­sciences is the lat­est IPO con­tender af­ter sub­mit­ting its pitch for a $114 mil­lion Nas­daq de­but, which will go to­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er CEO Bourla sug­gests phar­ma tar­iffs will fo­cus on US ad­ver­saries, not al­lies

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times